Metabolic Reprogramming in Osteosarcoma Cells

Osteosarcoma, the most common primary malignant bone tumour in adolescents and young adults, is defined by profound shifts in energy metabolism that support rapid growth, invasion and resistance to therapy. Cancer cells divert glucose from oxidative phosphorylation to aerobic glycolysis (the Warburg effect), upregulate glutamine breakdown to fuel biosynthesis, and rewire lipid pathways to generate membranes and signalling lipids. Mitochondrial function is often suppressed or altered, leading to imbalances in reactive oxygen species and redox homeostasis. Transcriptional regulators, metabolite-repair enzymes and nutrient transporters form integrated networks that sustain bioenergetic and anabolic demands. Understanding these interdependencies unveils metabolic vulnerabilities that can be exploited for biomarker development and targeted treatment strategies.

Research from Nature Portfolio

Recent work has unveiled a critical role for the mitochondrial enzyme FAHD1 in modulating osteosarcoma metabolism. Overexpression of FAHD1 in human osteosarcoma cells depletes mitochondrial oxaloacetate, dampening tricarboxylic acid cycle activity and substantially reducing reactive oxygen species production. Studies of catalytically enhanced and loss-of-function variants demonstrate that FAHD1 controls redox balance and mitochondrial respiration, suggesting that fine-tuning of metabolite-repair enzymes can restore mitochondrial function and may represent a novel approach to counter metabolic reprogramming in osteosarcoma.

Metabolic Reprogramming in Osteosarcoma Cells publication trend

The graph below shows the total number of articles in metabolic reprogramming in osteosarcoma cells across all publications each year (not limited to Nature Index journals).

Technical terms

Warburg effect: Preference for converting glucose to lactate under aerobic conditions instead of mitochondrial oxidation.

Tricarboxylic acid (TCA) cycle: Central mitochondrial pathway that oxidises acetyl-CoA to generate reducing equivalents and biosynthetic precursors.

Reactive oxygen species (ROS): Oxygen-derived molecules that can damage proteins, lipids and DNA but also act as signalling mediators.

Super-enhancer: Large clusters of regulatory DNA elements that drive high expression of genes defining cell identity or disease states.

Ferroptosis: Iron-dependent form of regulated cell death characterised by lipid peroxidation.

Redox balance: Equilibrium between oxidising and reducing species essential for cellular function and survival.

References

1. Mitochondrial enzyme FAHD1 reduces ROS in osteosarcoma. Scientific Reports (2024).
2. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma. Cell Death & Disease (2023).
3. The roles of glycolysis in osteosarcoma. Frontiers in Pharmacology (2022).
4. Comprehensive metabolomic profiling of osteosarcoma based on UHPLC-HRMS. Metabolomics (2020).